Vimentin a potential biomarker for therapeutic efficiency of HAART

Human immunodeficiency virus （HIV） is recognized to be one of the most destructive pandemics in recorded history. By 2011, approximately 34 million people had been infected globally. There were 2.5 million new HIV infections just in 2011 alone according to the Joint United Nations Programme on HIV/AIDS （UNAIDS）Report （2012）. With the use of highly active antiretroviral therapy （HAART）, the replication of HIV virus and the progression of HIV disease can be suppressed. However, during the life-long treatment of AIDS, HIV resistance and adverse drug reactions have become serious problems.